Pacific Biosciences Of California | PACB - Cash And Equivalent


Pacific Biosciences Of California reported $61M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Agilent USD 1.76B 49M Jun/2026
Bruker USD 184.9M 51.5M Jun/2026
Danaher USD 5.68B 1.33B Sep/2026
General Electric Aerospace USD 8.76B 581M Sep/2026
Illumina USD 1.29B 249M Sep/2026
Myriad Genetics USD 115.2M 9.2M Jun/2026
Pacific Biosciences Of California USD 61M 4.73M Jun/2026
Quidel USD 123.4M 17M Jun/2026
Revvity USD 1.02B 162.62M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Standard Biotools USD 265.77M 147.56M Mar/2026
Thermo Fisher Scientific USD 5.46B 1.4B Sep/2026
Waters USD 539M 77M Jun/2026